Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|April 21, 2020
Process2Clean®: Process Cleaning Detergents
Author(s)Veltek Associates, Inc
VAI’s Process2Clean®, Process Cleaning Detergents, are designed to remove process residues that could contaminate or adulterate further product manufacturing in the pharmaceutical, biotechnology, medical device, and R&D industries.
VAI’s GMP Process2Clean (P2C) cleaning products are specifically formulated for critical process cleaning applications. Each detergent is engineered to effectively remove numerous product residues found in pharmaceutical, biotechnology, medical device, and R&D industries. Process2Clean detergents successfully remove existent residues present in process manufacturing and reduce them down to acceptable trace residual limits. This critical process assures that product contact surfaces are clean prior to subsequent manufacturing and eliminates the possibility of product contamination or product adulteration.
Process2Clean detergents include an Alkaline Detergent, an Acid Based Detergent, a Hydroxyacetic Acid Cleaner, a General Purpose Cleaning Detergent, a Neutral pH Cleaning Additive, and a Chlorinated Alkaline Cleaning Detergent. This complete line of Process2Clean detergents are capable of removing a wide range of residues from inorganic to organic process soils and can be used in numerous cleaning systems from automated to manual.
Process2Clean detergents are formulated with Water for Injection (WFI) and are highly concentrated which translates into low cost per use. All shipments of Process2Clean are delivered with lot specific documentation and are completely validated with an extensive validation support package available. Process2Clean Detergents are available in 1, 5, 30, 55, and 275 gallon options either sterile or non-sterile.
Veltek Associates, Inc
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.